288 related articles for article (PubMed ID: 35196078)
1. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.
Zhang K; Erkan EP; Jamalzadeh S; Dai J; Andersson N; Kaipio K; Lamminen T; Mansuri N; Huhtinen K; Carpén O; Hietanen S; Oikkonen J; Hynninen J; Virtanen A; Häkkinen A; Hautaniemi S; Vähärautio A
Sci Adv; 2022 Feb; 8(8):eabm1831. PubMed ID: 35196078
[TBL] [Abstract][Full Text] [Related]
2. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
[TBL] [Abstract][Full Text] [Related]
3. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
6. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
7. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
9. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy.
Cole AJ; Panesso-Gómez S; Shah JS; Ebai T; Jiang Q; Gumusoglu-Acar E; Bello MG; Vlad A; Modugno F; Edwards RP; Buckanovich RJ
Clin Cancer Res; 2023 May; 29(10):1969-1983. PubMed ID: 36795892
[TBL] [Abstract][Full Text] [Related]
10. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
Cowin PA; George J; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz V; Friedlander M; McNally O; Quinn M; Campbell P; deFazio A; Bowtell DD;
Cancer Res; 2012 Aug; 72(16):4060-73. PubMed ID: 22896685
[TBL] [Abstract][Full Text] [Related]
11. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
[TBL] [Abstract][Full Text] [Related]
12. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
13. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Sriramkumar S; Metcalfe TX; Lai T; Zong X; Fang F; O'Hagan HM; Nephew KP
PLoS One; 2022; 17(8):e0271584. PubMed ID: 35921335
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile.
Lis R; Touboul C; Halabi NM; Madduri AS; Querleu D; Mezey J; Malek JA; Suhre K; Rafii A
J Transl Med; 2014 Mar; 12():59. PubMed ID: 24597747
[TBL] [Abstract][Full Text] [Related]
15. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Kim C; Gao R; Sei E; Brandt R; Hartman J; Hatschek T; Crosetto N; Foukakis T; Navin NE
Cell; 2018 May; 173(4):879-893.e13. PubMed ID: 29681456
[TBL] [Abstract][Full Text] [Related]
17. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.
Pietilä EA; Gonzalez-Molina J; Moyano-Galceran L; Jamalzadeh S; Zhang K; Lehtinen L; Turunen SP; Martins TA; Gultekin O; Lamminen T; Kaipio K; Joneborg U; Hynninen J; Hietanen S; Grénman S; Lehtonen R; Hautaniemi S; Carpén O; Carlson JW; Lehti K
Nat Commun; 2021 Jun; 12(1):3904. PubMed ID: 34162871
[TBL] [Abstract][Full Text] [Related]
18. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
19. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance.
Nowicka A; Marini FC; Solley TN; Elizondo PB; Zhang Y; Sharp HJ; Broaddus R; Kolonin M; Mok SC; Thompson MS; Woodward WA; Lu K; Salimian B; Nagrath D; Klopp AH
PLoS One; 2013; 8(12):e81859. PubMed ID: 24312594
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.
Gull N; Jones MR; Peng PC; Coetzee SG; Silva TC; Plummer JT; Reyes ALP; Davis BD; Chen SS; Lawrenson K; Lester J; Walsh C; Rimel BJ; Li AJ; Cass I; Berg Y; Govindavari JB; Rutgers JKL; Berman BP; Karlan BY; Gayther SA
J Exp Clin Cancer Res; 2022 Jul; 41(1):232. PubMed ID: 35883104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
